Sigman and AbbVie advance B.H. amination by analyzing bulky ligands
Citation: Ickes, A. R.; Liles, J. P.; Borlinghaus, N.; Henle, J.; Swiatowiec, R.; Kaushik, N. P.; Braje, W. M.; Harper, K. C.; Shekhar, S.; Sigman, M. S. Leveraging Data Science to Elucidate Ligand Features for Pd-Catalyzed Enantioretentive N -Arylations of cyclic a-Substituted Amines in Aqueous Media. J. Am. Chem. Soc. ASAP. https://pubs.acs.org/doi/10.1021/jacs.5c07224 Summary Figure: Background: To my best approximation, Buchwald-Hartwig aminations (or N-Arylation with Ar-X like Ullmann couplings) make up about 6% of all reactions medicinal chemists run (see The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates | Journal of Medicinal Chemistry ). That's an enormous percentage, given that the only more common classes are condensation, alkylation, and other Pd-catalyzed cross-coupling reactions are more common: From Cooper, T. W. J.; Campbell, I. B.; Macdonald, S. J. F., Angew. Chem. Int. Ed....